BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Ghazaleh S, Beran A, Aburayyan K, Nehme C, Patel D, Khader Y, Sharma S, Aziz M, Abdel-Aziz Y, Hammad T, Nawras A. Efficacy and safety of anticoagulation in non-malignant portal vein thrombosis in patients with liver cirrhosis: a systematic review and meta-analysis. Ann Gastroenterol 2021;34:104-10. [PMID: 33414629 DOI: 10.20524/aog.2020.0544] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
Number Citing Articles
1 Mathew C, Zumberg M. Evidence-Based Minireview: Should warfarin or a direct oral anticoagulant be used in patients presenting with thrombosis in the splanchnic or cerebral veins? Hematology Am Soc Hematol Educ Program 2021;2021:100-5. [PMID: 34889369 DOI: 10.1182/hematology.2021000319] [Reference Citation Analysis]
2 Wang HL, Lu WJ, Zhang YL, Nie CH, Zhou TY, Zhou GH, Zhu TY, Wang BQ, Chen SQ, Yu ZN, Jing L, Sun JH. Comparison of Transjugular Intrahepatic Portosystemic Shunt in the Treatment of Cirrhosis With or Without Portal Vein Thrombosis: A Retrospective Study. Front Med (Lausanne) 2021;8:737984. [PMID: 34671621 DOI: 10.3389/fmed.2021.737984] [Reference Citation Analysis]
3 Lucas F, Stecker MS, Pozdnyakova O, Connors JM, Battinelli EM. Rivaroxaban-calibrated chromogenic anti-Xa assay in cirrhosis: Use to rule out disseminated intravascular coagulation. Res Pract Thromb Haemost 2021;5:e12594. [PMID: 34646974 DOI: 10.1002/rth2.12594] [Reference Citation Analysis]
4 Mathew C, Zumberg M. Clots in unusual places: lots of stress, limited data, critical decisions. Hematology Am Soc Hematol Educ Program 2021;2021:92-9. [PMID: 34889361 DOI: 10.1182/hematology.2021000237] [Reference Citation Analysis]